Magnesio Solfato Monico

Magnesium sulfate, the active ingredient in Magnesio Solfato Monico, is an electrolyte presented as an injectable solution for intravenous use. It corrects hypomagnesemia and is employed in conditions such as preeclampsia‑related seizures, cardiac arrhythmias, and other magnesium‑deficiency states. GNH USA supplies Magnesio Solfato Monico as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Magnesium sulfate acts on electrolyte balance and neuromuscular stability, addressing several clinical conditions.

- Hypomagnesemia: restores serum magnesium levels to prevent neuromuscular and cardiac complications. - Prevention of seizures in preeclampsia/eclampsia: provides magnesium to reduce the risk of maternal seizures. - Torsades de pointes: stabilises cardiac repolarisation and helps terminate this polymorphic ventricular tachycardia. - Cardiac arrhythmias: corrects magnesium deficiency that can precipitate arrhythmic events. - Magnesium deficiency: supplies essential magnesium ions for metabolic and enzymatic functions.

Adverse reactions may occur with intravenous magnesium administration and should be monitored.

Common Side Effects: - Flushing or feeling of warmth at the infusion site. - Nausea or mild gastrointestinal discomfort. - Headache or dizziness. - Transient hypotension during rapid infusion. - Muscle weakness or fatigue. - Local irritation or pain at the injection site.

Serious or Rare Side Effects: - Severe hypotension leading to shock. - Cardiac arrest or profound bradyarrhythmias. - Respiratory depression or respiratory arrest. - Hypermagnesemia with neuromuscular blockade. - Anaphylactic or severe allergic reactions. - Persistent arrhythmias despite correction of magnesium levels.

Magnesium sulfate requires careful monitoring in specific patient populations and clinical situations. - Renal impairment: monitor serum magnesium and adjust infusion rate to avoid accumulation. - Cardiac disease: use cautiously and observe ECG for conduction changes. - Pregnancy: safety category unknown; weigh maternal benefits against potential fetal risks. - Concomitant neuromuscular blockers: may potentiate respiratory muscle weakness. - Electrolyte imbalance: avoid simultaneous high‑dose calcium or potassium without monitoring. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Magnesium sulfate can interact with several drug classes, influencing efficacy and safety.

Major Interactions (Avoid): - Calcium channel blockers: additive effects on cardiac conduction may cause severe bradycardia. - Neuromuscular blocking agents: potentiation can lead to prolonged respiratory paralysis. - Other magnesium‑containing products: risk of hypermagnesemia and related toxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: increase renal magnesium loss, possibly requiring dose adjustment. - ACE inhibitors or ARBs: may alter renal handling of magnesium, necessitating monitoring. - Aminoglycoside antibiotics: heightened risk of neuromuscular blockade when combined.